• Home
  • Cooley team
  • Resources
  • Cooley.com
Explore Close
Menu Close

Categories

InsightExperienceRegulatoryMarket UpdatesDeal TermsDeal LitigationEventsFiduciary DutiesCrossborderSPACsExitsFirm NewsDue DiligenceLitigationSPACs

Tags

AntitrustDelawareTrendsJudicialPrivate EquityDeal TermsLitigationRegulatoryCrossborderLife SciencesActivismTechEarnoutsFiduciary DutiesSECAppraisalCOVID-19CFIUSUnited KingdomDeal Litigation

Archives

May 2026 April 2026 March 2026 February 2026 January 2026 December 2025
  • Home
  • Cooley team
  • Resources
  • Cooley.com
  • Insight
  • Events

Cooley M&A

Key deals, decisions + trends

  • Insight
  • Events
Close
Experience

Sazerac Agrees to Acquire BuzzBallz

Brandon C on March 29, 2024
    SHARE

Cooley advised Sazerac, one of the world’s largest distilled spirits companies, on its agreement to acquire BuzzBallz, a woman-owned and family-operated distillery, winery and brewery in Texas.

Sazerac Agrees to Acquire BuzzBallz

Related

  • Lacework to Be Acquired by Fortinet In "Experience"
  • Tenable to Acquire Eureka Security In "Experience"
  • AuditBoard to Be Acquired by Hg for More Than $3 Billion In "Experience"
  • Cooley has handled 1,600+ M&A transactions for an aggregate value of $750+ billion since 2021, making our practice one of the most active in the world. Learn more

    Loading

    By signing up for Cooley blog/marketing messages, we will only process your personal information for the purpose of sending you marketing emails in accordance with our Privacy Policy. We do not sell your information or share it with any third-parties other than those necessary for this purpose. You can unsubscribe by clicking the unsubscribe link in any email we send you. You may have other rights with respect to your information which are detailed in our Privacy Policy.

    Recent M&A transactions

    • Ajax Therapeutics Acquired By Eli Lilly for Up to $2.3 Billion
    • Fluidstack Joint Venture to Issue $5.7 Billion in Senior Secured Notes
    • CrossBridge Bio Acquired by Eli Lilly and Co. for up to $300 Million
    • GreenSpark and ReMatter Combine to Form ReSpark
    • Neurocrine Acquisition of Soleno for $2.9 Billion
    • Korsana Biosciences Announces Merger With Cyclerion Therapeutics, Concurrent $380 Million Private Financing
    • Pro Football Focus Sale of Enterprise Business to Teamworks
    • Kezar Life Sciences Acquired by Aurinia Pharmaceuticals
    • TheGuarantors Announces Growth Investment From Warburg Pincus
    • Candid Therapeutics Announces Merger With Rallybio Corporation, Concurrent Private Financing of $505+ Million

    View more transactions

    Recent posts

    • SEC Exemptive Order Halves Minimum Tender Offer Period for Negotiated All-Cash Transactions
    • Cooley Market Talks – AI and the New Capital Dynamic: IPOs, M&A and What Comes Next
    • Yes, Your CEO’s AI Prompts May Be Discoverable (and Can Be Problematic)
    • Dual-Track Processes: How to Turbocharge Your Exit
    • Delaware Supreme Court Rejects Constitutional Challenges to DGCL Safe Harbor Amendments

    Disclaimer

    This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may hve been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.

    Previous
    Amolyt Pharma Agrees to Be Acquired by AstraZeneca in up to $1.05 Billion Cross-Border Transaction
    March 29, 2024
    Next
    Rubicon Technology Partners Announces Investment in Ascend Analytics
    March 29, 2024

    Cooley M&A

    Cooley has handled 1,600+ M&A transactions for an aggregate value of $750+ billion since 2021, making our practice one of the most active in the world. Learn more ›

    Recent

    • SEC Exemptive Order Halves Minimum Tender Offer Period for Negotiated All-Cash Transactions
    • Cooley Market Talks – AI and the New Capital Dynamic: IPOs, M&A and What Comes Next
    • Yes, Your CEO’s AI Prompts May Be Discoverable (and Can Be Problematic)
    • Dual-Track Processes: How to Turbocharge Your Exit
    • Delaware Supreme Court Rejects Constitutional Challenges to DGCL Safe Harbor Amendments

    Categories

    • Crossborder
    • Deal Litigation
    • Deal Terms
    • Due Diligence
    • Events
    • Exits
    • Experience
    • Fiduciary Duties
    • Firm News
    • Insight
    • Litigation
    • Market Updates
    • Regulatory
    • SPACs
    • SPACs